VERO BIOTECH INC
PharmaVERO BIOTECH INC is a pharmaceutical company focused on Cardiovascular, Respiratory. Key products include GENOSYL.
VERO BIOTECH INC's Key Drugs
VERO BIOTECH INC's core commercial portfolio centers on GENOSYL, spanning Cardiovascular and Respiratory — its most strategically important drugs approved in the last 15 years.
VERO BIOTECH INC's Recent FDA Approvals
New NDA/BLA approvals for VERO BIOTECH INC over the last two years — novel drugs only, excluding generics and label supplements.
VERO BIOTECH INC's Therapeutic Areas
VERO BIOTECH INC's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
VERO BIOTECH INC's Top Competitors
VERO BIOTECH INC's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
VERO BIOTECH INC Pipeline Snapshot
Active clinical trials for VERO BIOTECH INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GENOSYL leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling